<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Not too long ago, Special Purpose Acquisition Companies (SPACs) were the darlings of many private biotech firms, and vice versa. But enthusiam for this route to the public market has cooled considerably so far in 2022.
...read full article on GuruFocus
